Allison Betof Warner, MD, PhD

New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy https://bit.ly/4jwhLmm @drbetofmdphd.bsky.social #JITC #research #cancer

New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm
@drbetofmdphd.bsky.social #JITC #research #cancer 🧪

Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide

-for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR
-mDOR not reached

Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social

#ASCO25 @ascocancer.bsky.social

An entire day for solid tumor at #iwCART25! How far we’ve come in solid tumor cell therapy- 2 approvals since I was at this meeting last year! Looking forward to a great meeting.

The patient population is very small here. It’s only for synovial sarcoma, HLA A02+ (because it is a TCR) and MAGE A4 positive. It made sense to start small and expand from there. More centers are coming on board!

Pushing through boundaries in solid tumor cell therapy @stanford-cancer.bsky.social 📈
➡️ only 1 of 10 centers that offers sarcoma TCR-T
➡️ 50% DCR with TIL in melanoma brain mets and promising safety signal, no seizures or hemorrhages 🤞🙏 @drbetofmdphd.bsky.social @stevenartandi.bsky.social

Enjoyed discussing LAG3 targeting #melanoma w
@drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op!
www.medscape.org/viewarticle/...

Fantastic panel moderated by @drbetofmdphd.bsky.social - so many melanoma trials open/opening in the Bay Area. Great company, great colleagues, and great movement to make melanoma outcomes better here in the Bay Area, and everywhere 🖤 Thanks to ANCO for continuing to elevate oncology in NoCal ⛰️

What a great Melanoma & Developmental Therapeutics Session at the @ANCO_News conference! We discussed breakthroughs from 2024 and covered exciting new trial opportunities available in the Bay Area. What a team! 🤩 @funchainmd.bsky.social

Another landmark day for solid tumor cell therapy at @stanforduniversity.bsky.social Cancer Institute with our first infusion of FDA approved afami-cel (Tecelra), an engineered TCR T cell for synovial #sarcoma. We are thrilled to make this available to our patients!! #medsky #oncsky

New year, new adventures at #MedSky - oncology faculty opening for solid tumor cell therapy position 🧫@stanforduniversity.bsky.social, with preference for TIL/melanoma experience. Please contact me or @drbetofmdphd.bsky.social for more details!

Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs - OncoDaily Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs / Amalya Sargsyan, cancer, OncoDaily, Oncology, Sandra D'Angelo

Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs

oncodaily.com/dialogues/sa...

#Cancer #OncoDaily #Oncology #Medicine #Health

At the White House Cell and Gene Therapy Forum with my former @mskcancercenter.bsky.social colleague Kamal Menghrajani #cancermoonshot #whitehousecgt #genetherapy #CARTcells

Merry Christmas from @mskcancercenter.bsky.social 🎅🎄

Nicholas Restifo: A Breakthrough Year for T Cells - OncoDaily Nicholas Restifo: A Breakthrough Year for T Cells / cancer, CAR-T therapy, immunotherapy, Nature, Nicholas Restifo, OncoDaily, Oncology

A Breakthrough Year for T Cells - Nicholas Restifo

oncodaily.com/blog/nichola...

#Cancer #CARTTherapy #Immunotherapy #Nature #OncoDaily #Oncology #Medicine #Health

SOLID TUMOR CELL THERAPY position at Stanford. We are searching for a clinical investigator (MD, MD/PhD, or equiv) with expertise in solid tumor cell therapy, preference for experience with melanoma/TILs to join our growing team!

facultypositions.stanford.edu/en-us/job/49...

As an alum of @mskcancercenter.bsky.social, this brings back some really warm memories. The holiday hallway is such a labor of love which is emblematic of the best of MSK!

www.instagram.com/reel/DDrsAab...

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...

Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers.

www.merck.com/news/merck-p...

Wishing you happy and HEALTHY holidays from our @stanforduniversity.bsky.social Melanoma Oncology clinical and research team. We had a very festive celebration (including a grinch sighting!). We’ve grown tremendously over the last year- can’t wait for what’s in store for 2025!

📚 In conjunction with #ESMOImmuno24, we had our annual #ESMO #IOTECH Editorial Board meeting today - delighted to see many more academics now here 🦋.

🎯 EiC: @haanenjohn.bsky.social

Section Editors:
@michalbassani.bsky.social (NeoAg/TILs)
@danielathommen.bsky.social (Biomarkers/novel IO targets)...

...and more of our amazing #ESMO #IOTECH Editorial Board members:
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social

🦋 Follow for insights into #CancerImmunology!

From our recent webinar, Dr. Evan Lipson shares essential questions every melanoma patient should ask after their diagnosis about testing and treatment options. Empower yourself with knowledge and follow MRA to stay informed! #MelanomaAwareness

Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity #CancerCell

"Cell-intrinsic mannose metabolism is a physiological regulator of CD8+ T cell fate, decoupling proliferation/expansion from differentiation"

www.cell.com/cancer-cell/...

Method of the Year 2024: spatial proteomics - Nature Methods Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding biological complexity in health and disease.

SPATIAL PROTEOMICS is the Method of the Year 2024!!! 🤩🤩🤩

www.nature.com/articles/s41...

#ScienceSaturday

➡️ Did you know that some chemotherapies can enhance the immune response against #cancer?

❓ How might we potentiate this?

Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis - Nature Studies using mouse models of lung adenocarcinoma identify an association between age, iron homeostasis and tumour initiation potential that involves NUPR1 and lipocalin-2.

Ageing of stem cells reduces their capacity to form tumours #Nature @natureportfolio.bsky.social

"Most human cancers initiate at a young age, highlighting the importance of directing cancer prevention efforts towards young individuals."

www.nature.com/articles/s41...

Traveling home from the 2024 #ImmunotherapyBridge and #MelanomaBridge meetings in Napoli. We ate/drank ALL the food/wine, we debated, we collaborated, and we strengthened our community. I even got to debate one of my #she-roes @chrystalpaulos.bsky.social. Every year this meeting gets better!

Prof Hussein Tawbi #melanoma #Immunotherapy guru @mdanderson.bsky.social talks evolution of first line therapy. Highlights #LAG3 & lays out summary of what may be optimal for first line therapy & what looks promising/ #PD1 #CTLA4 #nivo #Ipi @bmsnews.bsky.social
#BRIDGE2024 @sitcancer.bsky.social

Yay 🙌! Our #CellTherapy for solid cancers community is growing here 🦋.

Welcome 👋
@drbetofmdphd.bsky.social 🇺🇸
@sklobuch.bsky.social 🇳🇱
@sophiawongyn.bsky.social 🇸🇬

#CancerImmunotherapy

Ok @chrystalpaulos.bsky.social and @funchainmd.bsky.social, you both win. I’m here. 🥳🤓

2) Another GREAT DEBATE! Prof. @chrystalpaulos.bsky.social @ #Emory debates with Prof. Allison Betof Warner #Stanford @stanfordpress.bsky.social / at start majority thinks it will be better to engineer TIL #Bridge2024 @sitcancer.bsky.social #adoptive #immunotherapy